Details:

Alternative Title:
Gonococcal Isolate Surveillance Project (GISP) annual report, 2001;GISP 2001 surveillance supplement;
Personal Author:
Wang, Susan A.
Corporate Authors:
National Center for HIV, STD, and TB Prevention (U.S.). Division of STD Prevention.
Description:
"With 361,705 gonorrhea cases reported in 2001, gonorrhea is the second most frequently reported communicable disease in the United States. Gonorrhea rates in the United States declined 73.8% during 1975-1997. However, in 1998, the reported rate of gonococcal infections in the United States (131.9 cases per 100,000 persons) increased by 7.8% compared with the 1997 rate (122.4 cases per 100,000 persons). In 2001, the gonorrhea rate was 128.5 cases per 100,000 population which represented little change from 1998. Gonorrhea rates remain high in the southeastern states, among minorities, and among adolescents of all racial and ethnic groups. The health impact of gonorrhea is largely related to its role as a major cause of pelvic inflammatory disease, which frequently leads to infertility or ectopic pregnancy. In addition, data suggest that gonorrhea facilitates HIV transmission. The treatment and control of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop resistance to antimicrobial agents. The appearance of penicillinase-producing N. gonorrhoeae (PPNG) and chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae (CMRNG) in the 1970s eventually led to the abandonment of these drugs as therapies for gonorrhea. The current CDC recommended primary therapies for gonorrhea are two broad-spectrum cephalosporins (ceftriaxone and cefixime), and three fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin). However, since the 1990s, fluoroquinolone-resistant N. gonorrhoeae (QRNG) have been reported from many parts of the world, including the United States. The increased prevalence of QRNG in Asia (where prevalence in several countries exceeds 40%), the Pacific Islands, Hawaii, and, most recently, California, prompted CDC to recommend that fluroquinolones not be used to treat patients with gonorrhea acquired in these areas with high QRNG prevalence." -- p. 1.
Content Notes:
Division of STD Prevention, prepared by Susan A. Wang, Alesia B. Harvey, Susan M. Conner, LuEtta Schneider and Hillard S. Weinstock.

"October 2002."

Also available via the World Wide Web.

Includes bibliographical references (p. 11-13).


Subjects:
[+]
Gonorrhea Sexually Transmitted Diseases
Document Type:
Report
Name as Subject:
Gonococcal Isolate Surveillance Project (U.S.) ; Gonococcal Isolate Surveillance Project (U.S.)
Gonococcal Isolate Surveillance Project (U.S.) ; Gonococcal Isolate Surveillance Project (U.S.) Less -
Genre:
Statistics ; Annual Reports
Statistics ; Annual Reports Less -
Place as Subject:
United States
Collection(s):
Stephen B. Thacker CDC Library collection
Main Document Checksum:
[+]
urn:sha256:2068b44a5c9c3611d861238d1fc74ff721e3f6fc80fd67a6ce39fb5b6c4a43a8
Download URL:
https://stacks.cdc.gov/view/cdc/24435/cdc_24435_DS1.pdf
File Type:

Supporting Files

• No Additional Files

More +